{
    "clinical_study": {
        "@rank": "31771", 
        "arm_group": [
            {
                "arm_group_label": "Pneumovax", 
                "arm_group_type": "Active Comparator", 
                "description": "Pneumovax, 1x 0.5 ml injection"
            }, 
            {
                "arm_group_label": "Prevenar 13", 
                "arm_group_type": "Experimental", 
                "description": "Prevenar 13, 1x 0.5 ml injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine whether patients with chronic lymphocytic leukaemia\n      (CLL) will benefit from vaccination with a 13-valent conjugated pneumococcal vaccine,\n      Prevenar13, compared with a conventional 23-valent capsular polysaccharide vaccine in terms\n      of immune response."
        }, 
        "brief_title": "Pneumococcal Vaccine in Untreated CLL Patients", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Untreated CLL patients all Rai stages (0 to IV), as early as possible after\n             diagnosis, always before any therapy with monoclonal antibodies and/or chemotherapy\n\n        Exclusion Criteria:\n\n          -  Immunosuppressive therapy planned to start within 1 month\n\n          -  Other malignancies\n\n          -  Corticosteroids or other immunosuppressive drugs\n\n          -  Previous allergic reaction to any vaccination in the past\n\n          -  Neutropenia (PMNs < 500 cells/mm3)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "154", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892618", 
            "org_study_id": "2009-012642-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prevenar 13", 
                "description": "13-valent pneumococcal conjugated vaccine", 
                "intervention_name": "Prevenar 13", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Pneumovax", 
                "description": "23-valent pneumococcal polysaccharide vaccine", 
                "intervention_name": "Pneumovax", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 17, 2013", 
        "location": {
            "contact": {
                "email": "eva@kimby.se", 
                "last_name": "Eva Kimby, Professor", 
                "phone": "+46 70854 01 88"
            }, 
            "facility": {
                "address": {
                    "city": "Stockholm", 
                    "country": "Sweden", 
                    "zip": "14186"
                }, 
                "name": "Karolinska University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia", 
        "overall_contact": {
            "email": "eva@kimby.se", 
            "last_name": "Eva Kimby, Professor", 
            "phone": "+46 708540188"
        }, 
        "overall_contact_backup": {
            "email": "tobsvensson@hotmail.com", 
            "last_name": "Tobias Svensson, MD", 
            "phone": "+46 705141539"
        }, 
        "overall_official": {
            "affiliation": "Karolinska University Hospital, SE-141 86 Stockholm, Sweden", 
            "last_name": "Eva Kimby, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Immune response to Pneumovax compared to immune response to Prevenar", 
            "safety_issue": "No", 
            "time_frame": "1 month post vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892618"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska University Hospital", 
            "investigator_full_name": "Eva Kimby", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Immune response to Pneumovax vs. Prevenar13", 
                "measure": "Serotype-specific immunoglobulin G (IgG) antibody levels", 
                "safety_issue": "No", 
                "time_frame": "1 and 6 months post vaccination"
            }, 
            {
                "description": "Immune response", 
                "measure": "Levels of opsonophagocytic antibodies (OPA)", 
                "safety_issue": "No", 
                "time_frame": "6 months post vaccination"
            }, 
            {
                "measure": "Serotype-specific IgG antibody levels by ELISA, geometric mean concentrations (GMCs)between arms", 
                "safety_issue": "No", 
                "time_frame": "1 and 6 months post vaccination"
            }
        ], 
        "source": "Karolinska University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karolinska University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}